Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 79 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vitiligo Vulgaris Clear all
Recruiting No phase listed Observational

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

NCT06491615
View directory record Official record
Conditions
Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy, Best Disease, Aniridia, Albinism
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Day to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2054
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 4, 2026, 7:51 AM EDT
Not listed Phase 2 Interventional

Treatment of Hypopigmented Scars With Bimatoprost

NCT06122090
View directory record Official record
Conditions
Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic, Cicatrix, Pigmentation Disorder, Burns Laser
Interventions
Bimatoprost, Saline
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 4, 2026, 7:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparative Study Using Dermabrasion vs CO2 Laser & Collagen Dressing vs Vaseline Gauze in MKTP

NCT02038257
View directory record Official record
Conditions
Vitiligo, Depigmented Scars, Depigmentation
Interventions
MKTP (melanocyte keratinocyte transplant procedure), Collagen Dressing, Vaseline Impregnated Gauze, Carbon Dioxide Laser, Dermabrasion
Procedure · Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 4, 2026, 7:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411
View directory record Official record
Conditions
Vitiligo
Interventions
Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 4, 2026, 7:51 AM EDT
Recruiting Phase 2 Interventional

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

NCT07105254
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
Roflumilast topical 0.3% foam
Drug
Lead sponsor
Derm Texas, PLLC
Network
Eligibility
2 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 4, 2026, 7:51 AM EDT
Completed Phase 2 Interventional

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

NCT03123016
View directory record Official record
Conditions
Vitiligo
Interventions
Apremilast, NB-UVB phototherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 4, 2026, 7:51 AM EDT
Recruiting Phase 2 Interventional

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

NCT07108283
View directory record Official record
Conditions
Nonsegmental Vitiligo
Interventions
Zasocitinib, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Bryant, Arkansas • Fountain Valley, California • Fremont, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 4, 2026, 7:51 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 4, 2026, 7:51 AM EDT
Active, not recruiting Phase 2 Interventional

Daily Topical Rapamycin for Vitiligo

NCT05342519
View directory record Official record
Conditions
Vitiligo
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 4, 2026, 7:51 AM EDT
Recruiting Phase 2 Interventional

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
GIA632, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Birmingham, Alabama • Fountain Valley, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 4, 2026, 7:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Questionnaire and Laboratory Data on Vitiligo Vulgaris

NCT01206374
View directory record Official record
Conditions
Vitiligo Vulgaris
Interventions
Not listed
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 4, 2026, 7:51 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

NCT06548360
View directory record Official record
Conditions
NonSegmental Vitiligo
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 4, 2026, 7:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

NCT06113445
View directory record Official record
Conditions
NonSegmental Vitiligo
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Hoover, Alabama • Irvine, California • Santa Monica, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 4, 2026, 7:51 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

NCT04487860
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
AS012, Placebo
Drug
Lead sponsor
Ache Laboratorios Farmaceuticos S.A.
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Bryant, Arkansas • Fremont, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 4, 2026, 7:51 AM EDT
Completed Phase 2 Interventional

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

NCT05298033
View directory record Official record
Conditions
Vitiligo
Interventions
Crisaborole 2 % Topical Ointment, PF-07038124 0.01% topical ointment, NBUVB phototherapy, Sham phototherapy, Vehicle
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 4, 2026, 7:51 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo

NCT05053022
View directory record Official record
Conditions
Vitiligo
Interventions
Skinpen Precision System
Device
Lead sponsor
Crown Laboratories, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 4, 2026, 7:51 AM EDT
Completed Phase 2 Interventional Results available

Tofacitinib for Immune Skin Conditions in Down Syndrome

NCT04246372
View directory record Official record
Conditions
Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, Vitiligo, Psoriasis
Interventions
Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 4, 2026, 7:51 AM EDT
Completed Phase 1 Interventional

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

NCT01430195
View directory record Official record
Conditions
Vitiligo
Interventions
Afamelanotide, Narrow-Band UVB Light Treatment
Drug · Procedure
Lead sponsor
Clinuvel Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 4, 2026, 7:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo

NCT00367224
View directory record Official record
Conditions
Vitiligo
Interventions
6 to 9 ultraviolet B treatments, Skin biopsies
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 4, 2026, 7:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Potential Research Study Participant Registry

NCT00710489
View directory record Official record
Conditions
Acne, Actinic Keratosis, Dysplastic Nevi, Eczema, Psoriasis, Skin Cancer, Rosacea, Leg Ulcers, Foot Ulcers, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 4, 2026, 7:51 AM EDT
Not listed No phase listed Observational

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

NCT05084417
View directory record Official record
Conditions
Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
Interventions
N/A This is an observational study
Other
Lead sponsor
OM1, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 4, 2026, 7:51 AM EDT
Not listed Phase 1 Interventional

Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

NCT02281058
View directory record Official record
Conditions
Vitiligo
Interventions
Abatacept
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 4, 2026, 7:51 AM EDT
Completed Phase 3 Interventional Results available

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

NCT04057573
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
34
States / cities
Gilbert, Arizona • Fremont, California • Irvine, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 4, 2026, 7:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

NCT04896385
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Fountain Valley, California • Irvine, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 4, 2026, 7:51 AM EDT